Stem Cell Therapy for Dementia Associated With Alzheimer’s Disease and Ischemic Stroke is under clinical development by Stemedica Cell Technologies and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Stem Cell Therapy for Dementia Associated With Alzheimer’s Disease and Ischemic Stroke’s likelihood of approval (LoA) and phase transition for Dementia Associated With Alzheimer’s Disease took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Stem Cell Therapy for Dementia Associated With Alzheimer’s Disease and Ischemic Stroke Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Stem Cell Therapy for Dementia Associated With Alzheimer’s Disease and Ischemic Stroke overview

Stem cell therapy is under development for the treatment of dementia associated with Alzheimer's disease. The investigational therapy is a combination of neural stem cell (NSC) and mesenchymal stem cells (MSCs). it was also under development for ischemic stroke.

Stemedica Cell Technologies overview

Stemedica Cell Technologies (Stemedica) is a Biotechnology company. It offers regenerative medicine, healthcare products. The company manufactures and develops adult ischemic tolerant stem cells and stem cell derived factors. It provides allogeneic adult stem cell products such as mesenchymal stem cells derived from adult bone marrow, neural stem cells obtained from donated brain tissue and retinal epithelial cells. Stemedica’s products are used in clinical trials for the treatment of cardiac, ophthalmological, alzheimer’s, ischemic stroke, neurological, and dermatological indications. The company operates through universities and research institutions to advance adult stem cell treatments through translational medicine. It operates in the US and Switzerland. Stemedica is headquartered in San Diego, California, the US.

Quick View Stem Cell Therapy for Dementia Associated With Alzheimer’s Disease and Ischemic Stroke LOA Data

Report Segments
  • Innovator
Drug Name
  • Stem Cell Therapy for Dementia Associated With Alzheimer’s Disease and Ischemic Stroke
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.